

Medical Developments International Limited (MVP)
ACN 106 340 667
ASX Announcement

Mr Chris Rossidis appointed to CEO

Medical Developments International Ltd (ASX: MVP) announced today the appointment of Mr Chris Rossidis as Chief Executive Officer.

Chris Rossidis, 42, has worked in the pharmaceutical industry for over 18 years in a number of senior management roles.

Mr Rossidis has particularly strong experience in Sales, Marketing and Business Development having worked for Eli Lilly, GlaxoSmithKline and CSL. Most recently, he was the General Manager of EpiPharm; a division of Clinuvel Pharmaceuticals Limited which was recently purchased by Geneparm Australasia Ltd.

David Williams, Chairman, said, "Chris' business development experience and skills combined with his broad Australian and International contact base is what is needed to aggressively grow the company from its current strong base."

Mr Rossidis said, "I am delighted to be given this opportunity with Medical Developments. The company has exceptional products and there is significant potential for growth. My immediate focus will be to increase current national and international sales as well as increase international registrations, which will accelerate MVP's global business returns."

End

For further information, contact David Williams on 0414 383 593.